Update on antithrombotic agents in secondary stroke prevention.
Recurrent stroke is a major cause of morbidity and mortality among stroke survivors. With improved survival after first ischemic stroke, stroke recurrence may account for a greater share of the future annual cost of stroke-related health care. Despite advances in stroke prevention strategies and treatments, stroke recurrence is still the major threat to any stroke survivor. This review discusses antithrombotic therapy in secondary stroke prevention which has a major impact in clinical practice.
Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
Tatjana
T
Rundek
Vanja
V
Basić-Kes
Sandra
S
Morović
Vida
V
Demarin
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D055502:Secondary Prevention; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents